In addition to its previous approvals for Crohn's and psoriasis:
J&J's Stelara clinches ulcerative colitis nod to back up declining Remicade
Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. | Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on...
www.fiercepharma.com